Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injectable solution for intramuscular, intravenous, subcutaneous use. It treats autoimmune disorders and several types of cancer in both adult and pediatric patients.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is employed across inflammatory and oncologic disease pathways to modify disease activity and improve outcomes. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: induces tumor cell death. - Osteosarcoma: impedes tumor growth and metastasis.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Transient elevation of liver enzymes. - Mild leukopenia or thrombocytopenia. - Skin rash or photosensitivity.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Significant bone marrow suppression leading to infection. - Renal impairment or failure. - Life‑threatening hypersensitivity reactions. - Rare neurotoxicity presenting as seizures or encephalopathy.

Methotrexate therapy requires careful monitoring and patient education to minimise risks. - Baseline and periodic blood counts: monitor for cytopenias. - Liver function tests: assess for hepatotoxicity. - Renal function: adjust dose in impairment. - Pregnancy contraindication: avoid in women of childbearing potential; use effective contraception. - Vaccination: do not administer live vaccines during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels. - Penicillins and sulfonamides: potentiate bone‑marrow suppression. - Trimethoprim‑sulfamethoxazole: heighten risk of hematologic toxicity. - Live vaccines: may cause severe infection.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclosporine: additive immunosuppression. - Proton pump inhibitors: may affect renal clearance. - Leucovorin rescue: adjust timing to avoid antagonism. - Alcohol: increases hepatic risk.